SpliceBio vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AAV cargo limit.
About
SpliceBio is a gene therapy company whose protein trans-splicing platform overcomes the 4.7-kilobase cargo limit of adeno-associated viral (AAV) vectors — the primary delivery vehicle for gene therapy — unlocking treatments for large-gene diseases previously untreatable. The company raised $135 million in Series B financing co-led by Sanofi Ventures and EQT Life Sciences in June 2025, and dosed its first patient in Phase 1/2 Part B for SB-007 in Stargardt disease in January 2026.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.